Adjunction of a MEK inhibitor to Vemurafenib in the treatment of metastatic melanoma results in a 60% reduction of acute kidney injury
Crossref DOI link: https://doi.org/10.1007/s00280-017-3300-2
Published Online: 2017-04-10
Published Print: 2017-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Teuma, Cécile
Pelletier, Solenne
Amini-Adl, Mona
Perier-Muzet, Marie
Maucort-Boulch, Delphine
Thomas, Luc
Laville, Maurice
Fouque, Denis
Dalle, Stéphane
License valid from 2017-04-10